Tramadol: A valuable treatment for pain in Southeast Asian countries by Vijayan, Ramani et al.
eCommons@AKU
Department of Anaesthesia Medical College, Pakistan
October 2018
Tramadol: A valuable treatment for pain in
Southeast Asian countries
Ramani Vijayan
University Malaya Medical Centre, Kuala Lumpur, Malaysia
Gauhar Afshan
Aga Khan University, gauhar.afshan@aku.edu
Khalid Bashir
Hameed Latif Hospital, Lahore, Pakistan
Mary Cardosa
Hospital Selayang, Selangor, Malaysia
Madhur Chadha
Primus Hospital and Fortis Group of Hospitals, New Delhi, India
See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_anaesth
Part of the Anesthesiology Commons
Recommended Citation
Vijayan, R., Afshan, G., Bashir, K., Cardosa, M., Chadha, M., Chaudakshetrin, P., Hla, K. M., Joshi, M., Javier, F. O., Kayani, A. G.
(2018). Tramadol: A valuable treatment for pain in Southeast Asian countries. Journal of Pain Research, 11, 2567-2575.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_anaesth/354
Authors
Ramani Vijayan, Gauhar Afshan, Khalid Bashir, Mary Cardosa, Madhur Chadha, Pongparadee
Chaudakshetrin, Khin Myo Hla, Muralidhar Joshi, Francis O. Javier, and Asif Gul Kayani
This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_anaesth/354
© 2018 Vijayan et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Journal of Pain Research  2018:11 2567–2575
Journal of Pain Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2567
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/JPR.S162296 
Tramadol: a valuable treatment for pain in 
Southeast Asian countries
Ramani Vijayan,1 Gauhar Afshan,2 
Khalid Bashir,3 Mary Cardosa,4 
Madhur Chadha,5 Pongparadee 
Chaudakshetrin,6 Khin Myo Hla,7 
Muralidhar Joshi,8 Francis O Javier,9 
Asif Gul Kayani,10 Andi Takdir 
Musba,11 Sasikaan Nimmaanrat,12 
Dwi Pantjawibowo,13 Jocelyn C 
Que,14 Palanisamy Vijayanand15
1Department of Anaesthesiology, University 
Malaya Medical Centre, Kuala Lumpur, 
Malaysia; 2Department of Anaesthesiology, 
The Aga Khan University, Karachi, Pakistan; 
3Department of Anaesthesia, Hameed Latif 
Hospital, Lahore, Pakistan; 4Department 
of Anaesthesiology, Hospital Selayang, 
Selangor, Malaysia; 5Department of Pain 
Medicine, Primus Hospital and Fortis 
Group of Hospitals, New Delhi, India; 
6Pain Management Clinic, Department 
of Anesthesiology, Siriraj Hospital, 
Mahidol University, Bangkok, Thailand; 
7Department of Physical Medicine & 
Rehabilitation, Yangon General Hospital, 
University of Medicine-1, Yangon, Myanmar; 
8Department of Anaesthesia & Pain 
Medicine, Virinchi Hospitals, Hyderabad, 
India; 9Pain Management Center, St Luke’s 
Medical Center, Metro Manila, Philippines; 
10Department of Anesthesiology, Kulsum 
International Hospital, Islamabad, Pakistan; 
11Department of Anesthesiology, Faculty of 
Medicine, Hasanuddin University, Makassar, 
Indonesia; 12Department of Anesthesiology, 
Faculty of Medicine, Prince of Songkla 
University, Hatyai, Songkhla, Thailand; 
13Department of Anesthesiology, Intensive 
Therapy, and Hospital Pain Management, 
Premier Bintaro Hospital, South Tangerang, 
Indonesia; 14Center for Pain Medicine, 
Department of Anesthesiology, Faculty 
of Medicine and Surgery, University of 
Santo Tomas, Manila, Philippines; 15Pain 
Management Department, Sri Ramakrishna 
Hospital, Coimbatore, Tamil Nadu, India
Background: The supply of controlled drugs is limited in the Far East, despite the prevalence of 
health disorders that warrant their prescription. Reasons for this include strict regulatory frameworks, 
limited financial resources, lack of appropriate training amongst the medical profession and fear 
of addiction in both general practitioners and the wider population. Consequently, the weak opioid 
tramadol has become the analgesic most frequently used in the region to treat moderate to severe pain.
Methods: To obtain a clearer picture of the current role and clinical use of tramadol in Southeast 
Asia, pain specialists from 7 countries in the region were invited to participate in a survey, using 
a questionnaire to gather information about their individual use and experience of this analgesic.
Results: Fifteen completed questionnaires were returned and the responses analyzed. Tramadol 
is used to manage acute and chronic pain caused by a wide range of conditions. Almost all the 
specialists treat moderate cancer pain with tramadol, and every one considers it to be significant 
or highly significant in the treatment of moderate to severe non-cancer pain. The reasons for 
choosing tramadol include efficacy, safety and tolerability, ready availability, reasonable cost, 
multiple formulations and patient compliance. Its safety profile makes tramadol particularly 
appropriate for use in elderly patients, outpatients, and for long-term treatment. The respondents 
strongly agreed that tighter regulation of tramadol would reduce its medical availability and 
adversely affect the quality of pain management. In some countries, there would no longer be 
any appropriate medication for cancer pain or the long-term treatment of chronic pain.
Conclusions: In Southeast Asia, tramadol plays an important part in the pharmacological man-
agement of moderate to severe pain, and may be the only available treatment option. If it were to 
become a controlled substance, the standard of pain management in the region would decline.
Keywords: tramadol, questionnaire, indications, efficacy, safety, controlled substance
Introduction
The unmet need for effective pain management remains high, particularly in low and 
middle income countries. The World Health Organization (WHO) estimates that tens 
of millions of people experience moderate to severe pain every year without access 
to treatment, including 5.5 million with terminal cancer and a million with late stage 
HIV infection.1 Research has shown that the availability of controlled opioid analge-
sics – such as morphine, hydrocodone and fentanyl – is very limited in many parts of 
the world, including the Asian region.2–4
WHO Expert Committees advise the United Nations Commission on Narcotic 
Drugs about pharmaceutical agents which should be designated controlled substances – 
ie, have their manufacture, possession, or use regulated by a government – on the basis 
of their individual therapeutic profiles and risk of abuse. Tramadol is a centrally acting 
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analgesic combining both opioid and non-opioid mechanisms 
of action that has been used to treat moderate to (moderately) 
severe cancer and non-cancer pain for several decades.5 It has 
been assessed several times by the WHO, but in each case 
it was decided not to bring it under international control.6
Intercontinental Marketing Services Kilochem statistics 
show that – except for non-steroidal anti-inflammatory 
drugs (NSAIDs) and paracetamol – tramadol and tramadol-
containing products are the analgesics most often used in 
clinical practice in a large group of Asian countries, with 
increasing consumption over time (Figure 1).
To obtain a clearer picture of the role and clinical use of 
tramadol in the Far East, pain specialists from 7 countries in 
the region were invited to participate in a pilot survey, which 
was drawn up in compliance with the Healthcare Profes-
sional Code of the European Federation of Pharmaceutical 
Industries and Associations.7 A questionnaire was developed 
to gather information about their use of tramadol, their 
experience of its abuse potential in clinical practice, and 
the influence of regulatory controls on medical availability.
Tramadol
Tramadol [2-(dimethylaminomethyl)–1-(3-methoxyphenyl)
cyclohexanol] is a racemic 1:1 mixture of two enantiomers, 
(+)-tramadol and (−)-tramadol, which differ in their poten-
cies at opioid receptors and monoamine uptake sites.8 Their 
mechanisms of action are complementary and synergistic: the 
(+)-enantiomer is a selective agonist at the µ-opioid receptor 
and inhibits serotonin reuptake, while the (–)-enantiomer 
mainly inhibits noradrenaline uptake.9,10 Furthermore, the 
(+)-enantiomer is rapidly metabolized to mono-O-desmeth-
yltramadol (M1 metabolite), which binds to the µ-opioid 
receptor with an affinity two orders of magnitude higher than 
that of the parent compound and ~1/10 that of morphine.9,11
Tramadol is extensively metabolized in the liver by O- 
and N-demethylation and by conjugation reactions to form 
glucuronides and sulfates. The elimination of both tramadol 
and its metabolites is predominantly via the kidneys, with 
about 30% of the dose excreted in the urine as the parent 
drug and the rest excreted as metabolites.12
The contraindications for treatment with tramadol include 
acute respiratory depression, head injury, raised intracranial 
pressure, acute intoxication and uncontrolled epilepsy.13
Methods
The questionnaire shown in Table 1 was emailed to 17 pain 
specialists who expressed an interest in participating, in India 
(3), Indonesia (3), Malaysia (2), Myanmar (2), Pakistan (3), 
Figure 1 Tramadol consumption in Asia compared to controlled opioids.
Notes: Consumption data from Quintiles IMS Kilochem 2015 (Bangladesh Retail, China, Hong Kong, India, Indonesia, Japan, Jordan Retail, Kazakhstan, Kuwait Retail, Lebanon 
Retail, Malaysia, Pakistan Retail, Philippines, Saudi Arabia Retail, Singapore, South Korea, Sri Lanka Retail, Taiwan, Thailand, Turkey, UAE Retail, Vietnam); estimated PTD 
calculation based on WHO ATC DDD of the respective substance, except for buprenorphine and fentanyl transdermal patches (units sold multiplied by wearing time).
Abbreviations: ATC, Anatomical Therapeutic Chemical classification system; DDD, defined daily dosage; IMS, Intercontinental Marketing Services; PTD, patient treatment 
days; WHO, World Health Organization.
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Table 1 Questionnaire on the role of tramadol in pain management
With regards to your personal experiences with tramadol
1. In which indications do you use tramadol?
Click here to enter text.
2. What is the main reason for you to prescribe tramadol?
Click here to enter text.
3. In your opinion, what are the main advantages/benefits of tramadol (in general, in comparison to other analgesics, eg, other opioids, or 
NSAIDs)?
Click here to enter text.
4. With regards to its safety and tolerability, how do you see tramadol compared to other opioids available in your country?
Click here to enter text.
5. Based on your experiences, do you consider the abuse potential of tramadol lower than the abuse potential of other opioids?
Click here to enter text.
With regards to the use of tramadol in your country
6. How do you rate the significance of tramadol for the treatment of the following pain indications/special patient groups in your country? Please 
indicate for all listed indications/special patient groups: not significant (NS)/moderately significant (MS)/significant (S)/highly significant (HS)
For indications/special patient groups, you rated tramadol as “significant” or “highly significant”:
What are the main reasons for the high significance of tramadol in those indications/special patient groups?
Indication Significance rating
(NS, MS, S, or HS)
If rating is significant or highly significant,  
what are the main reasons?
Cancer pain NS MS S HS Click here to enter text.
Non-cancer pain NS MS S HS Click here to enter text.
Acute post-op pain NS MS S HS Click here to enter text.
Acute musculoskeletal pain NS MS S HS Click here to enter text.
Chronic low back pain NS MS S HS Click here to enter text.
Osteoarthritis NS MS S HS Click here to enter text.
Neuropathic pain NS MS S HS Click here to enter text.
Any other NS MS S HS Click here to enter text.
Special patient groups
Pain treatment in adult patients NS MS S HS Click here to enter text.
Pain treatment in children NS MS S HS Click here to enter text.
Pain treatment in elderly patients NS MS S HS Click here to enter text.
7. Is tramadol used as an alternative to strong opioids in your country?
Click here to enter text.
8. Are you aware of any official reports of misuse or abuse of tramadol in patients with chronic pain in your country?
Click here to enter text.
9. If strong regulations (further controls/higher scheduling) regarding tramadol would be implemented in your country, which consequences do 
you foresee in regard to:
•	 impact on medical availability of tramadol
	 in the hospital
	 in the outpatient setting
	 Click here to enter text.
•	 the treatment of patients with moderate to severe pain.
	 Which treatment alternatives would you substitute for tramadol?
	 Click here to enter text.
	 What would be the impact of this substitution in terms of efficacy, safety and convenience of the alternative treatment?
	 Click here to enter text.
•	 The quality of pain management in your country?
	 Click here to enter text.
10. Is tramadol included in national guidelines? Please specify
Click here to enter text.
11. Any other comments
Click here to enter text.
Abbreviation: NSAID, non-steroidal anti-inflammatory drugs.
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the Philippines (2) and Thailand (2). The questions were 
formulated to identify their individual reasons for prescribing 
tramadol and the conditions for which they prescribed it, as 
well as the significance of tramadol in the management of 
pain and the likely impact of tighter regulation on treatment 
– both in hospital and in the community – in their own coun-
tries. A total of 15 completed questionnaires were returned 
and the responses analyzed in November 2016.
Results
Indications for which tramadol is 
prescribed
According to the experts, tramadol is used in the management 
of moderate to severe acute and chronic pain caused by a 
wide range of conditions. Their rating of the significance of 
tramadol as a treatment option for various pain indications 
is shown in Figure 2.
Almost all the specialists treat moderate cancer pain 
with tramadol, a modality that is supported in the lit-
erature.13–15 Most of them rated it as significant or highly 
significant in managing this condition. Important factors 
influencing their choice of analgesic was tramadol’s effi-
cacy in both nociceptive and neuropathic pain,16 which 
often occur concurrently in cancer pain,17 its position as a 
step two analgesic on the WHO “pain ladder”, and patients’ 
preference for it over low-dose strong opioids. Respondents 
from India, Indonesia and Pakistan also stated that there is 
limited or no availability of controlled opioid analgesics 
in their countries. Although tramadol does not have the 
same potency as strong opioid analgesics such as morphine 
for treating severe cancer pain, tramadol is often the only 
option available.
Every one of the respondents considered tramadol to be 
either significant or highly significant in the treatment of 
moderate to severe non-cancer pain in their home country, 
specifically mentioning acute indications such as labor pain, 
postoperative and post-traumatic pain, and chronic indica-
tions such as low back pain and osteoarthritis. It is considered 
an alternative to NSAIDs or strong opioids, particularly 
suitable for elderly patients or those with poor liver and/or 
renal function.18
The majority of respondents rated tramadol as sig-
nificant or highly significant in the management of acute 
postoperative pain and acute musculoskeletal pain. Specific 
examples quoted were the combination of tramadol with 
WHO step one analgesics or as an alternative to them, and 
its use as a step-down analgesic from strong opioids fol-
lowing surgery.
Efficacy must be carefully balanced against safety when 
long-term treatment is required for chronic conditions such 
as osteoarthritis and chronic low back pain, and around 
three-quarters of respondents regarded tramadol as being 
significant or highly significant in managing these conditions. 
Factors contributing to this rating included its efficacy in 
mixed pain (ie, with nociceptive and neuropathic compo-
nents), and its favorable benefit/risk ratio in prolonged use. 
It was specifically noted that the safety issues associated with 
NSAIDs often limit their use, particularly in chronic pain 
patients and the elderly, so tramadol is frequently substituted 
– an approach which is reflected in the current literature.19,20
Figure 2 Significance of tramadol in various acute and chronic pain indications.
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Over three-quarters of the specialists also rated the use 
of tramadol in neuropathic pain as significant or highly 
 significant in their own country, mostly as a second line 
option after drugs such as gabapentin. This is in line with 
international recommendations.21
One respondent from India also prescribes tramadol for 
fibromyalgia; both tramadol monotherapy and tramadol/
acetaminophen combination tablets have been shown to 
reduce pain levels associated with this poorly understood 
condition.22,23
In the case of specific patient groups, around three- 
quarters of respondents considered the current use of tra-
madol to be significant or highly significant for adult and 
elderly patients. The proportion was lower for children, at less 
than one-third, primarily because the specialists have much 
less clinical experience with pediatric patients. The reasons 
given for the high significance accorded to tramadol in pain 
management are listed in Table 2, and broadly mirror the 
factors influencing the choice of analgesic outlined below.
Reasons for prescribing tramadol
Efficacy
The main reason for choosing tramadol to manage pain 
in Asia – reflected by its high usage – is the wide-ranging 
effectiveness resulting from its unique multimodal 
mechanisms of action, which are well established.16,24–27 
The responses confirm that tramadol effectively treats 
both acute and chronic pain, as well as nociceptive and 
neuropathic pain. This makes it particularly valuable for 
managing pain states such as cancer pain and chronic 
low back pain, which often have both nociceptive and 
neuropathic components.28 In the case of chronic pain, its 
risk-benefit profile in long-term use offers advantages over 
other drugs, such as NSAIDs. Some respondents referred 
specifically to the advantages of tramadol’s classification 
Table 2 Reasons for the high significance of tramadol in pain 
management
•	 Efficacy in moderate to severe nociceptive and neuropathic pain
•	 Good tolerability and safety profile compared to NSAIDs and strong 
opioids, especially in elderly patients requiring long-term treatment
•	 Ready availability
•	 Multimodal mechanism of action, giving “opioid-sparing” effect
•	 Possibility of combination with other analgesics
•	 Availability of multiple formulations
•	 Lower risk of addiction than strong opioids
•	 Non-controlled prescription
•	 Easy to use
•	 Good patient compliance
Abbreviation: NSAIDs, non-steroidal anti-inflammatory drugs.
as a WHO step two compound, positioned after simple 
analgesics (NSAIDs,  cyclooxygenase-2 (COX-2) inhibi-
tors, paracetamol) and before the need for strong opioids. 
In countries with limited or no access to strong opioids, 
tramadol may be the only reliably available stronger anal-
gesic for pain patients.
Safety and tolerability
Another decisive factor in the choice of tramadol is its safety 
profile. It is frequently chosen in preference to NSAIDs, 
which may cause renal and gastrointestinal impairment in 
long-term use. Selective COX-2 inhibitors and especially 
NSAIDs are associated with an elevated risk of severe gas-
trointestinal, renal and cardiovascular side effects,29–32 and the 
risk increases with the duration of treatment. It is therefore 
recommended that the lowest dose of these agents to control 
symptoms should be prescribed for the shortest time.33 Tra-
madol is not associated with these side effects, and several 
responders specifically cited its suitability for long-term use 
in patients with chronic pain as a strong influence on their 
choice of analgesic.
The side effect profile of strong opioids may include 
nausea and vomiting, hypotension, tachycardia, respiratory 
depression, abuse and neurological symptoms.34 While the 
incidence of nausea and vomiting is not significantly different 
between tramadol and strong opioids, especially in opioid-
naïve patients and depending upon the route of administra-
tion, the general experience of the specialists is that tramadol 
is well tolerated. Patients have fewer typical µ-opioid side 
effects, particularly a reduced risk of respiratory depression,25 
which has been confirmed by randomized clinical trials.35–37 
This is in line with the observation from Vazzana et al that 
the advantages of tramadol over other opioid medications are 
its unique pharmacological profile, the lower incidence of 
typical µ-opioid side effects and its lower abuse potential.38 
Like many other opioids, tramadol can induce seizures.39 
However, these occur mainly after administering tramadol 
in doses which exceed the recommended upper limit or in 
combination with medicinal products that lower the seizure 
threshold. In patients with epilepsy or who are susceptible 
to seizures it should be avoided. The concomitant use of 
tramadol and serotonergic drugs may cause serotonin toxicity.
The respondents generally considered the abuse potential 
of tramadol to be either lower or much lower than that of 
strong opioids, and that it presents a lower risk of addic-
tion. This is supported by experimental and clinical find-
ings40–42 and reflects the current view of the WHO, which 
concluded in its 2014 assessment that international control 
Journal of Pain Research  2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2572
Vijayan et al
status is not warranted. Nevertheless, substances with a low 
abuse potential may lead to a level of abuse under certain 
circumstances, which may require targeted national measures 
to address the specific problem. This has been the case in 
Thailand, where the abuse of tramadol – mainly by adoles-
cents – has led to targeted measures by the local authorities.
Overall, the experts concluded that the safety profile of 
tramadol makes it particularly appropriate for use in elderly 
patients, in the outpatient setting, and for longer periods of time.
Easy availability at reasonable cost
Tramadol is easily obtained on prescription in most Southeast 
Asian countries and – as it is a generic analgesic – is relatively 
inexpensive. Conversely, strong opioids are generally subject 
to restrictive legal controls and may not even be available to 
hospitals. The cost of morphine is generally low, but that of 
newer opioids such as oxycodone, fentanyl and buprenorphine 
– or specific formulations – is usually higher than that of tra-
madol. Also, supplies of strong opioids tend to be intermittent 
and, unlike tramadol, only a limited range of formulations is 
available. According to one respondent from India, tramadol 
is the only non-NSAID analgesic obtainable in that country 
in a formulation designed for oral administration.
Multiple formulations
The range of formulations available in the Far East includes 
1) drops, capsules and tablets for oral use; and 2) solutions 
for intramuscular, intravenous and subcutaneous injection. 
Oral formulations are produced in both immediate release and 
sustained release versions. Among the benefits of sustained 
release are that it decreases peak plasma concentrations and 
thereby reduces adverse effects, while the concomitant simpler 
dosing regimen may improve patient compliance. In much 
of the Far East a range of formulations is available, allowing 
the clinician considerable scope to individualize treatment.
Patient compliance
Most respondents find that tramadol is well tolerated and one 
specifically mentioned patient compliance as a factor in the 
choice of analgesic. In some countries such as the Philippines 
there is also a cultural influence; morphine has a stigma and 
many patients believe they will become addicted to it, so com-
pliance is poor. By contrast, tramadol is more readily accepted.
The potential impact of more stringent 
controls on availability and treatment
Respondents strongly agreed that tighter regulation would 
lead to a significant reduction in the medical availability 
of tramadol, especially in the outpatient setting. In order to 
compensate for this reduced availability, other analgesics 
would be substituted; mainly NSAIDs, COX-2 inhibitors and 
– in the hospital setting in a few countries – strong opioids. 
If NSAIDs or COX-2 inhibitors were to be prescribed, their 
lower efficacy means that fewer patients would achieve sat-
isfactory pain relief, especially those with conditions which 
have a neuropathic pain component. There would also be a 
higher incidence of serious side effects on the gastrointes-
tinal, renal and cardiovascular systems, especially over the 
long term or in elderly patients. Other possible consequences 
mentioned by respondents include the higher cost of alterna-
tive analgesics and a decline in patient compliance, owing 
to patients’ fears of addiction to strong opioids and their 
possible side effects.
All the respondents stated that the quality of pain manage-
ment would be adversely affected, so many patients would 
be left without appropriate treatment for moderate to severe 
pain, especially in the outpatient setting. As strong opioids 
are not readily available in several countries, including India 
and Pakistan, some respondents foresee they would no lon-
ger have any appropriate medication for cancer pain or the 
long-term treatment of chronic pain. The experts’ opinion 
is supported by a survey, conducted by the International 
Narcotics Control Board (INCB) in 2013,43 which confirmed 
the negative impact of an international scheduling on the 
availability of tramadol. In total, 72% of responders (33 of 46 
countries) expressed concern that the introduction of control 
measures would limit accessibility to tramadol and make 
doctors more reluctant to prescribe it, which reflects past 
experience of national tramadol controls leading to reduced 
medical availability.43,44
Discussion
Tramadol has become the analgesic mostly frequently used 
in the Far East to treat moderate to severe pain. It is readily 
available and relatively cheap. This survey indicates that the 
utilization of tramadol is based upon several factors:
•	 proven efficacy in treating various cancer and non-cancer 
indications, supported by its inclusion in national/medical 
society guidelines in 5 of the 7 countries surveyed;
•	 safety and tolerability compared to NSAIDs and strong 
opioids;
•	 ease of storage and prescription compared to controlled 
strong opioids;
•	 after major surgery, it can be used as a step-down anal-
gesic following patient-controlled or epidural analgesia; 
and
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•	 it can be combined with NSAIDs, COX-2 inhibitors or 
paracetamol to augment analgesia.
The experts’ responses clearly indicate that tramadol 
is a valuable option to treat moderate to severe pain of 
diverse origin. It is prescribed when non-opioids such as 
paracetamol, NSAIDs and COX-2 inhibitors provide insuf-
ficient  analgesia, are not tolerated, or are contra-indicated, 
and where strong opioids are not justified or are unavailable. 
This use is reflected by tramadol being included in a number 
of national and international guidelines,45–47 and is in line 
with its role in therapy as described in the international 
literature.25,48,49
Chronic pain is an important public health issue. The Dec-
laration of Montreal states that access to pain management 
is a fundamental human right, and that all people with pain 
should have access to appropriate assessment and treatment 
without discrimination.50 However, studies have concluded 
that 5.5 billion people (~83% of the world’s population) live 
in countries with low to non-existent access to controlled 
opioid analgesics, and only 460 million (7%) have adequate 
access.1,2 The reasons for poor accessibility include strict 
national regulations, lack of training in their use, and fear 
of addiction among both health care professionals and the 
general population. The United Nations’ 1961 Single Conven-
tion on Narcotic Drugs states the dual obligation to ensure 
that controlled substances are available for medical purposes 
and to protect populations against abuse and diversion.51 The 
importance of making these substances available for those 
who need them is continuously highlighted, eg, by inter-
national human rights organizations, the WHO, the INCB, 
the World Health Assembly and regional intergovernmental 
organizations.
In the Far East, the limited supply of controlled drugs is 
illustrated by the fact that in 2005 the whole of Asia accounted 
for only 3% of the world’s consumption of opioids, compared 
to 67% for Europe.52 The situation has changed little since: 
between 2001–2003 and 2011–2013 the worldwide con-
sumption of opioids has more than doubled, yet in India it 
increased by only 10% and in Myanmar it actually declined.53 
A number of barriers to wider use in the region have been 
identified; these include onerous regulatory frameworks, 
restricted financial resources, and an absence of appropriate 
training amongst the medical profession.53 In some countries 
a fear of addiction among both general practitioners and the 
wider population also acts as a disincentive.53,54 The dispar-
ity between the availability of opioid analgesics and the 
prevalence of health disorders that warrant their prescription 
remains a major cause of concern. Moreover, the prevalence 
of certain pain syndromes (eg, joint pain, neuralgias) is pro-
jected to increase further in the coming decades, owing to the 
rapidly increasing elderly population55; eg, Asia is projected 
to see a >60% increase in the number of older people (60 
years and over) between 2015 and 2030.56
If tramadol were to become a controlled substance, the 
responses reveal a widely held belief that the medical avail-
ability of tramadol would be severely curtailed in the region, 
especially in the outpatient setting, and the unmet need for 
pain relief would increase significantly.
A key limitation of this survey is the small sample size, 
but the responses from the disparate countries were highly 
consistent over the range of questions.
Conclusions
In Southeast Asia, tramadol or tramadol-containing anal-
gesics play an important part in the pharmacological man-
agement of moderate to severe pain. It provides a stronger 
– and for many patients a safer – alternative to high doses 
of NSAIDs or low doses of morphine, oxycodone or other 
strong opioids. In addition, there are many situations where 
tramadol is the only available option for treating moderate to 
severe pain, accessible to inpatients and outpatients in regions 
where controlled opioids are unobtainable. Pain specialists 
in the region consider that access to tramadol would clearly 
be reduced if it were to become a controlled substance. As a 
direct consequence, the quality of pain management would 
decline, particularly for patients who require longer term 
treatment, and for some patients appropriate medication 
would no longer be available.
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